Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19622954 | 0.89 | CYP1A2 (0.54) | CYP1A2TDP1ALDH1A1TSHRMAPK1 | |
| SCHEMBL28530574 | 0.86 | CYP1A2 (0.57) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL27800545 | 0.86 | CYP1A2 (0.57) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL27961047 | 0.84 | CYP1A2 (0.68) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL4942315 | 0.84 | CYP1A2 (0.58) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL95713 | 0.83 | CYP1A2 (0.54) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL95714 | 0.83 | CYP1A2 (0.54) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL28046747 | 0.83 | CYP1A2 (0.54) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL5333075 | 0.82 | CYP1A2 (0.66) | CYP1A2TDP1ALDH1A1GPR35TSHR | |
| SCHEMBL10403856 | 0.82 | CYP1A2 (0.60) | CYP1A2TDP1ALDH1A1GPR35TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| EP-3813832-B1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) | 2022-11-09 | — | — | EP | disclosed |
| CN-107849594-B | Deamination of organophosphorus nucleosides | 科技学专业学院有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3813832-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2021-05-05 | — | — | EP | disclosed |
| CN-107849594-A | The deaminizating of organophosphor nucleosides | 科技学专业学院有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-1399399-A1 | REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-6648998-B2 | Mixture; replacement of trinitrotoluene with (mono or di)nitro aromatic compounds | ALLIANT TECHSYSTEMS INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030140993-A1 | Reduced sensitivity, melt-pourable tritonal replacements | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003002485-A1 | REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002486-A1 | REDUCED SENSITIVITY, MELT-POURABLE TNT REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| US-20030005988-A1 | Reduced sensitivity, melt-pourable TNT replacements | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2003-01-09 | — | — | US | disclosed |
| EP-1248755-A1 | REDUCED SENSITIVITY MELT-CAST EXPLOSIVES | ALLIANT TECHSYSTEMS INC. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020038682-A1 | Reduced sensitivity melt-cast explosives | Northrop Grumman Innovation Systems, Inc. | 2002-04-04 | — | — | US | disclosed |
| WO-2001046091-A1 | REDUCED SENSITIVITY MELT-CAST EXPLOSIVES | DOLL, DANIEL, W. | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046092-A1 | REDUCED SENSITIVITY MELT-CAST EXPLOSIVES | ALLIANT TECHSYSTEMS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | UGT1A3, UGT1A1, UGT1A6 | CYP1A2 34/4885TDP1 1650/4885ALDH1A1 14/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | CYP1A2 34/4885TDP1 1650/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.